[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Colorado Prevention Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100516720","phase-3-a-study-to-determine-the-efficacy-and-safety-of-finerenone-on-morbidity-and-mortality-among-hospitalized-heart-failure-patients-100516720",false,"NCT06008197","A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients","Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)","REDEFINE-HF","Inclusion Criteria:\n\n* Provide written informed consent\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Current hospitalization or recently discharged (during or within 30 days of discharge) with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher)\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg\u002FmL or B-type natriuretic peptide (BNP) ≥125 pg\u002FmL for patients without atrial fibrillation (AF); or elevated NTproBNP ≥1500 pg\u002FmL or BNP ≥375 pg\u002FmL for patients with AF\n\nExclusion Criteria:\n\n* Current or planned long-term treatment with a mineralocorticoid receptor antagonist (MRA)\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Estimated glomerular filtration rate (eGFR) \\\u003C25 mL\u002Fmin\u002F1.73m² or potassium \\>5.0 mmol\u002FL at screening\n* Acute myocardial infarction due to plaque rupture, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Hemodynamically significant (severe) uncorrected primary cardiac valvular disease\n* Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or known pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)","ALL","18 Years",{"count":20,"type":21},5200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.",[27,28],"Heart Failure","Acute Heart Failure",[30,31,32,33],"Heart failure","Preserved ejection fraction","Mildly reduced ejection fraction","Hospitalized","RECRUITING","2026-05-01",{"date":37,"type":38},"2026-05-06","ACTUAL",{"date":40,"type":38},"2024-01-17",{"date":42,"type":21},"2027-12",{"name":44,"class":45},"Colorado Prevention Center","OTHER",299,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100618685","implementation-of-an-algorithm--and-multi-professional-team-supported-strategy-to-improve-lipid-management-of-patients-with-atherosclerotic-cardiovascular-disease-100618685","NCT07334834","Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease","Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease: OPTIMIZE ASCVD","OPTIMIZE ASCVD","Inclusion Criteria:\n\n* Provided informed consent\n* Age \\>18 years inclusive at screening\n* Documented atherosclerotic vascular disease including:\n\n  * Coronary artery disease (prior revascularization, myocardial infarction, imaging evidence of coronary atherosclerosis)\n  * Peripheral artery disease (prior revascularization, amputation, ankle: brachial index (ABI) ≤ 0.90, imaging evidence of extra-coronary atherosclerosis)\n  * Carotid artery disease (prior endarterectomy or stenting of the extracranial carotid artery or imaging evidence of carotid atherosclerosis)\n  * Imaging evidence of atherosclerotic vascular disease in a non-coronary vascular bed (e.g. aorta, mesenteric, renal)\n  * LDL-C \\>70mg\u002FdL\n\nExclusion Criteria:\n\n* Any reason that, in the opinion of the investigator, the patient would be unable to adhere to the protocol for the duration of the study (e.g. terminal diagnosis, metastatic cancer) or in whom participation might result in harm.\n* Planned active titration of current lipid-lowering therapy\n* Myocardial infarction or arterial revascularization within prior 30 days",{"count":56,"type":21},100,[58],"NA","This is a randomized, controlled, collaborative, multicenter, pilot implementation science study evaluating the hypothesis that algorithm- and multi-professional team-supported lipid management reduces low density lipoprotein-cholesterol (LDL-C) compared with usual care in patients with atherosclerotic cardiovascular disease (ASCVD).",[61],"Hyperlipidemia",[63,64,65,66,67],"Lipid Management","Atherosclerotic Cardiovascular Disease","Coronary Artery Disease","Peripheral Artery Disease","Carotid Artery Disease","2026-01-22",{"date":70,"type":38},"2026-01-23",{"date":72,"type":38},"2025-12-10",{"date":74,"type":21},"2027-07",{"name":44,"class":45},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100518700","phase-3-a-study-to-evaluate-finerenone-on-clinical-efficacy-and-safety-in-patients-with-heart-failure-who-are-intolerant-or-not-eligible-for-treatment-with-steroidal-mineralocorticoid-receptor-antagonists-100518700","NCT06033950","A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists","A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)","FINALITY-HF","Inclusion Criteria:\n\n* Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Symptomatic HFrEF per protocol defined criteria\n* Not on sMRA due to history of intolerance, contraindication, or ineligibility for treatment\n* Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)\n\nExclusion Criteria:\n\n* Treatment with non-steroidal MRA (nsMRA)\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* eGFR \\\u003C 25 mL\u002Fmin\u002F1.73m² and \u002F or potassium \\> 5.0 mmol\u002FL\n* Acute myocardial infarction, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days or planned\n* Prior or planned heart transplant\n* Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure\n* Symptomatic bradycardia or second- or third-degree heart block without a pacemaker\n* Cardiomyopathy due to known acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction\n* Probable alternative cause of participant's HF\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, or moderate or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)\n* Any other condition or therapy which would make the participant unsuitable for the study\n* Concurrent or previous participation in another interventional clinical study using an investigational agent within 30 days prior to randomization",{"count":86,"type":21},2600,[24],"Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).",[27],[91,92],"Reduced ejection fraction","Symptomatic heart failure","2025-03-06",{"date":95,"type":38},"2025-03-11",{"date":97,"type":38},"2024-08-20",{"date":99,"type":21},"2028-04",{"name":44,"class":45},8,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100517992","phase-3-a-study-to-determine-the-efficacy-and-safety-of-finerenone-and-sglt2i-in-combination-in-hospitalized-patients-with-heart-failure-confirmation-hf-100517992","NCT06024746","A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)","Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)","CONFIRMATION","Inclusion Criteria:\n\n* Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Current hospitalization or recently discharged with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg\u002FmL or B-type natriuretic peptide (BNP) ≥125 pg\u002FmL according to the local lab for patients in sinus rhythm; or elevated NTproBNP ≥1500 pg\u002FmL or BNP ≥375 pg\u002FmL for patients with atrial fibrillation (AF), measured during the current hospitalization or in the 72 hours prior to hospital admission\n* Fulfillment of protocol defined stabilization criteria (if randomized during hospitalization)\n* Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide, torsemide, bumetanide).\n* Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes or prior history of diabetic ketoacidosis\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Treatment with non-steroidal mineralocorticoid receptor antagonist (MRA) or SGLT2i\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² and\u002For potassium \\>5.0 mmol\u002FL\n* Acute myocardial infarction, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Prior or planned heart transplant\n* Hemodynamically significant uncorrected primary cardiac valvular disease as primary cause of heart failure\n* Cardiomyopathy due to acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)\n* Any other condition or therapy which would make the patient unsuitable for this study",{"count":111,"type":21},1500,[24],"Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.",[27],[27,33],{"date":95,"type":38},{"date":118,"type":38},"2024-07-09",{"date":120,"type":21},"2026-08",{"name":44,"class":45},15,""]